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A B S T R A C T - The integrity of myelin sheaths is maintained by oligodendrocytes and Schwann cells respectively 
in the central nervous system (CNS) and in the peripheral nervous system. The process of demyelination consisting 
of the withdrawal of myelin sheaths from their axons is a characteristic feature of multiple sclerosis, the most 
common human demyelinating disease. Many experimental models have been designed to study the biology of 
demyelination and remyelination (repair of the lost myelin) in the C N S , due to the difficulties in studying 
human material. In the ethidium bromide (an intercalating gliotoxic drug) model of demyelination, CNS 
remyelination may be carried out by surviving oligodendrocytes and/or by cells differentiated from the primitive 
cell lines or either by Schwann cells that invade the CNS. However, some factors such as the age of the experimental 
animals, intensity and time of exposure to the intercalating chemical and the topography of the lesions have 
marked influence on the repair of the tissue. 
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Biologia da reparação de lesões desmielinizantes do sistema nervoso central: uma avaliação 
RESUMO - A integridade da bainha de mielina é fornecida pelos oligodendrócitos e pelas células de Schwann, 
no sistema nervoso central (SNC) e no sistema nervoso periférico, respectivamente. O fenômeno de 
desmielinização refere-se à remoção das bainhas de mielina de axônios e este fato é característico na esclerose 
múltipla, a doença desmielinizante do SNC mais comum no homem. Muitos modelos experimentais têm sido 
utilizados para o estudo da biologia da desmielinização e remielinização no SNC, face à dificuldade de estudo 
de material humano. No modelo experimental da droga intercalate, gliotóxica, brometo de etídio, a remielinização 
do SNC pode ser efetuada por oligodendrócitos sobreviventes à lesão e/ou oriundos de diferenciação de linhagens 
celulares mais primitivas e por células de Schwann que invadem o SNC. No entanto, fatores como a idade dos 
animais, a intensidade, e o tempo de exposição ao agente intercalante e a topografia da lesão influenciam 
significativamente a reparação da lesão. 
PALAVRAS-CHAVE: desmielinização tóxica, remielinização, sistema nervoso central, sistema 
nervoso periférico. 
The central nervous system (CNS) develops from a thickened area of the embryo ectoderm, the neural 
plate. The neural tube formation and the neural crest development will respectively give rise to the CNS and 
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most of the peripheral nervous system (PNS). Thus histologically the nervous tissue of the C N S is made up of 
neurons and glial cells from a single layer of proliferating neural epithelium or by cells of the primitive neural 
tube (for details see Moore20; Pereira & Graça1 4) and a non-collagenic extracellular matrix3. 
Raff et a ! 2 6 and Raff2 7 defined the neuroglia according to the expression of cellular antigens along their 
fetal development, using immunocytochemical methods. Astrocytes may be classified into two distinct classes: 
Type I (former protoplasmic), RAN-2* and Type I I (former fibrous) A2B5 \ Type II astrocytes assist interfascicular 
oligodendrocytes in the formation and maintenance of the myelin sheath and in saltatory conduction27. 
Interrelationships between Type II astrocytes and oligodendrocytes (GC*) come from a common embryonic 
origin, the 0-2A cell 2 7. 
In the CNS oligodendrocytes put many layers of their cytoplasmic membrane around one or more axons, 
forming a spiralled structure, the myelin sheath under the form of short tubes named internodes1. In the PNS 
myelin sheath formation is made up by Schwann cells. Each Schwann cell forms one 1 mm long intemode in a 
single axon composed of up to 300 concentric lamellae1. Oligodendrocytes form similar segments although they 
extend cytoplasmic processes that may myelinate many axons simultaneously, in some cases up to two hundred10. 
This fact and the proliferation potentialities of Schwann cells explain the larger repair capacity of demyelinated 
lesions in the PNS. 
DEMYELINATION/REMYELINATION 
The phenomenon of demyelination consists of the removal of myelin sheaths from normal C N S and 
PNS axons usually with perivascular infiltration of small lymphocytes, red blood cells and large mononuclear 
cells 2 9. Such myelin loss is frequently referred as primary demyelination5 and must be differentiated from 
degeneration of myelin sheaths following axonal degeneration, known as Wallerian degeneration. 
Many experimental models have been used to study the biology of primary demyelination and 
remyelination that take part in spontaneous CNS diseases. Those models seek to mimic demyelinating pathologies 
and to search for physiological features of those diseases including the behavior of glial cells involved with 
repair processes after the action of harmful agents. Among these demyelinating C N S diseases, multiple scleroses 
(MS) and distemper, in humans and canines respectively, are the most striking, being the most marked histological 
feature of such disorders the presence of persistent demyelinated areas which consistently fail to remyelinate 
and are responsible for the symptoms of the disease. 
Inoculation of lytic viruses that infect oligodendrocytes, such as Theiler's virus"1; induction of 
immunologic reactions against cells that express viral antigens, such as those of Semliki Forest virus1 5; induction 
of in vivo immunological reactions by intradermal inoculation of emulsified brain1 7; in vitro addition of 
myelinotoxic E A E (experimental allergic encephalomyelitis) serum16; systemic administration of toxic substances 
such as cuprizone19 and hypocholesterolemic drugs32; local injection of either myelinotoxic or gliotoxic agents 
such as lysolecithin6,6-aminonicotinamide4 and ethidium bromide (EB) 5 - 9 - 1 2 , 1 3 - 2 3 - 3 1 ' 3 4 , are among the experimental 
models which have been developed in order to clarify the cellular processes of demyelination and remyelination. 
As in individuals suffering of MS there is a persistent failure in the repair of lost myelin sheaths, the 
viewpoint that remyelination did not occur in the C N S was sustained for many years. However in 1961, Bunge 
et al. 7 firstly reported C N S remyelination after demyelination following cerebral fluid barbotage in the cat. 
Albeit the remyelinating process is viable, it depends upon factors as the intensity, the exposition time to the 
demyelinating agent10 as well as the C N S areas involved23. In the E B model of demyelination when the lesion is 
inflicted to the spinal cord of Wistar rats, remyelination may be accomplished either by surviving oligodendrocytes 
over the edges of the lesions or Schwann cells that invade the C N S along subpial and perivascular areas (Fig 1 
to 4 ) 9 1 3 . When E B is injected into the brain stem of Wistar rats, remyelinating-oligodendrocytes- repair myelin 
sheaths chiefly around the periphery of the lesions and Schwann cells remyelinate axons also in places other 
than subpial and perivascular areas2 3'2 5. 
Although remyelination is well recognized both in experimental models and spontaneous diseases the 
origin of oligodendrocytes and Schwann cells remains a controversial issue. Three hypothesis are proposed for 
the presence of remyelinating oligodendrocytes: 1) they would be surviving cells from the edges of the lesions in 
MS cases** 2) oligodendrocytes would be able of generating remyelinating daughter-cells19, although the absence 
of morphological demonstration of oligodendrocyte mitosis in adult individuals, is an intriguing feature; 3) 
oligodendrocytes might come from the differentiation of the adult 0-2A lineage cells, once autoradiographic 
experiments show poor oligodendrocyte proliferation in adult mice21. Oligodendroglial replacement in adult 
animals is being studied by immunocytochemical identification of the adult 0-2A lineage cells and to find out 
which stimuli trigger the proliferation and differentiation of cells of such lineage constitute the goal of numerous 
investigations33. However the most relevant feature is that oligodendrocytes may be a replacement source since 
profuse astrocytic gliosis, observed in most lesions of the C N S , does not hinder remyelination22. 
On the other hand, the presence of myelinating Schwann cells in the C N S has been depicted in normal28 
as well as in several demyelinating processes related to human diseases such as MS 1 4 and many of the experimental 
models mentioned above. The way and stimulus for the migration of Schwann cells into demyelinating lesions 
in the spinal cord has been comprehensively discussed by Graça9. The origin of Schwann cells in those lesions 
appears to be related to blood vessels, pial and dorsal nerve root9-". 
Although remyelination is a fact in most experimental models of demyelination, it is necessary to 
understand the mechanisms that interfere with that function in MS lesions. One limiting factor could be the 
gliosis" made up by Type I astrocytes although oligodendrocyte remyelination in gliotic areas in the brain of 
Wistar rats23 and humans2 has been consistently reported. Thus, astrocytosis per se can not be blamed for the 
lack of remyelination 2 X 2 5 . The main problem seems to be the lack of appropriate stimuli for the differentiation 
of cells from the O- 2A lineage. Astrocytic gliosis and the integrity of the blood brain barrier, on the other hand, 
could interfere with the CNS invasion of the Schwann cells2 3. 
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